Real-time disaster intelligence, alerts, and response tools.
Tuesday, March 3, 2026
[ad_1] The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of targeted treatments for inherited and acquired cardiac disorders. Additionally, emerging candidates such as LX2020 […]
[ad_1] The amyotrophic lateral sclerosis market is expected to grow owing to the increasing prevalence of the disease, along with the promising emerging pipeline therapies, such as Masitinib (AB Sciences), PrimeC (Neurosense Therapeutics), RNS60 (Revalesio), […]
[ad_1] The basal cell carcinoma market is anticipated to experience a positive shift due to the better uptake of existing drugs, the expected market launch of new therapies such as Remetinostat (Medvir), STP705 (Sirnaomics), SP-002 […]
[ad_1] The mycosis fungoides market is anticipated to progress steadily, influenced by the relatively small pipeline of emerging therapies. Leading candidates such as Soligenix’s HYBRYTE and Innate Pharma’s Lacutamab, among others, reflect a strong industry […]
[ad_1] The mitochondrial myopathies treatment market is expected to grow steadily, driven by the recent approval of FORZINITY and KYGEVVI, improved diagnosis, and rising awareness. Additionally, the expected launch of therapies such as Sonlicromanol (Khondrion; […]
